Faldoni Flávia L C, Villacis Rolando A R, Canto Luisa M, Fonseca-Alves Carlos E, Cury Sarah S, Larsen Simon J, Aagaard Mads M, Souza Cristiano P, Scapulatempo-Neto Cristovam, Osório Cynthia A B T, Baumbach Jan, Marchi Fabio A, Rogatto Silvia R
International Research Center, A.C.Camargo Cancer Center, São Paulo 01508-010, Brazil.
Department of Clinical Genetics, University Hospital of Southern Denmark, 7100 Vejle, Denmark.
Cancers (Basel). 2020 Sep 30;12(10):2816. doi: 10.3390/cancers12102816.
Inflammatory breast cancer (IBC) is a rare and aggressive type of breast cancer whose molecular basis is poorly understood. We performed a comprehensive molecular analysis of 24 IBC biopsies naïve of treatment, using a high-resolution microarray platform and targeted next-generation sequencing (105 cancer-related genes). The genes more frequently affected by gains were (75%) and (71%), while frequent losses encompassed (71%) and (58%). Increased MYC and MDM4 protein expression levels were detected in 18 cases. These genes have been related to IBC aggressiveness, and MDM4 is a potential therapeutic target in IBC. Functional enrichment analysis revealed genes associated with inflammatory regulation and immune response. High homologous recombination (HR) deficiency scores were detected in triple-negative and metastatic IBC cases. A high telomeric allelic imbalance score was found in patients having worse overall survival (OS). The mutational profiling was compared with non-IBC (TCGA, = 250) and IBC ( = 118) from four datasets, validating our findings. Higher frequency of and variants were detected compared to non-IBC, while showed similar frequency. Variants in mismatch repair and HR genes were associated with worse OS. Our study provided a framework for improved diagnosis and therapeutic alternatives for this aggressive tumor type.
炎性乳腺癌(IBC)是一种罕见且侵袭性强的乳腺癌类型,其分子基础尚不清楚。我们使用高分辨率微阵列平台和靶向新一代测序(105个癌症相关基因)对24例未经治疗的IBC活检组织进行了全面的分子分析。受增益影响更频繁的基因是(75%)和(71%),而频繁缺失包括(71%)和(58%)。在18例病例中检测到MYC和MDM4蛋白表达水平升高。这些基因与IBC的侵袭性有关,并且MDM4是IBC中的一个潜在治疗靶点。功能富集分析揭示了与炎症调节和免疫反应相关的基因。在三阴性和转移性IBC病例中检测到高同源重组(HR)缺陷评分。在总生存期(OS)较差的患者中发现了高端粒等位基因不平衡评分。将突变谱与来自四个数据集的非IBC(TCGA,=250)和IBC(=118)进行比较,验证了我们的发现。与非IBC相比,检测到和变体的频率更高,而显示出相似的频率。错配修复和HR基因中的变体与较差的OS相关。我们的研究为这种侵袭性肿瘤类型的改进诊断和治疗选择提供了一个框架。